Neonatal Sepsis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major neonatal sepsis markets are expected to exhibit a CAGR of 7.12% during 2024-2034.
The neonatal sepsis market has been comprehensively analyzed in IMARC's new report titled "Neonatal Sepsis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neonatal sepsis is a potentially life-threatening condition characterized by a systemic infection that occurs in newborn infants within the first month of life. It is primarily caused by bacteria, although other pathogens like viruses and fungi can also be responsible. The symptoms of the ailment can be subtle and nonspecific, making early diagnosis challenging. Common signs include fever, difficulty feeding, irritability, rapid breathing, lethargy, jaundice, and a change in skin color or temperature. Since these symptoms can overlap with several other newborn conditions, medical professionals must maintain a high index of suspicion when evaluating an infant for possible sepsis. The diagnosis of the ailment usually includes a combination of clinical evaluation, blood tests, and laboratory assessments. Blood cultures are crucial for identifying the specific pathogen responsible for the infection, while various other workups may reveal elevated white blood cell counts, abnormal levels of inflammatory markers, or signs of organ dysfunction.
The escalating incidences of numerous risk factors, such as premature birth, low birth weight, maternal infection during pregnancy, prolonged rupture of membranes, etc., are primarily driving the neonatal sepsis market. In addition to this, the inflating utilization of effective therapeutic approaches, including antibiotics, antiviral medications, and antifungal agents, for the prompt management and treatment of the disease is also creating a positive outlook for the market. Moreover, the widespread adoption of neonatal intensive care units (NICUs) equipped with advanced medical technologies and skilled healthcare professionals is further bolstering the market growth. These specialized units are instrumental in providing critical care and monitoring to neonates suffering from sepsis, thus ensuring timely intervention and improving clinical outcomes. Apart from this, the rising awareness and emphasis on preventive measures, such as maternal screening for infections during pregnancy, early detection of risk factors, and the promotion of breastfeeding, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive therapies, including mechanical ventilation and fluid management, since they help in stabilizing the patient's physiological parameters and avert life-threatening scenarios like organ failure, is also augmenting the market growth. Furthermore, the increasing demand for immunotherapy, involving the use of immunoglobulins and cytokine inhibitors, to mitigate the severity of the condition is expected to drive the neonatal sepsis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the neonatal sepsis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neonatal sepsis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neonatal sepsis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neonatal sepsis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neonatal sepsis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neonatal sepsis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the neonatal sepsis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neonatal sepsis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neonatal sepsis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neonatal sepsis across the seven major markets?
What is the number of prevalent cases (2018-2034) of neonatal sepsis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neonatal sepsis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with neonatal sepsis across the seven major markets?
What is the size of the neonatal sepsis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neonatal sepsis?
What will be the growth rate of patients across the seven major markets?
Neonatal Sepsis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neonatal sepsis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neonatal sepsis market?
What are the key regulatory events related to the neonatal sepsis market?
What is the structure of clinical trial landscape by status related to the neonatal sepsis market?
What is the structure of clinical trial landscape by phase related to the neonatal sepsis market?
What is the structure of clinical trial landscape by route of administration related to the neonatal sepsis market?
The neonatal sepsis market has been comprehensively analyzed in IMARC's new report titled "Neonatal Sepsis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Neonatal sepsis is a potentially life-threatening condition characterized by a systemic infection that occurs in newborn infants within the first month of life. It is primarily caused by bacteria, although other pathogens like viruses and fungi can also be responsible. The symptoms of the ailment can be subtle and nonspecific, making early diagnosis challenging. Common signs include fever, difficulty feeding, irritability, rapid breathing, lethargy, jaundice, and a change in skin color or temperature. Since these symptoms can overlap with several other newborn conditions, medical professionals must maintain a high index of suspicion when evaluating an infant for possible sepsis. The diagnosis of the ailment usually includes a combination of clinical evaluation, blood tests, and laboratory assessments. Blood cultures are crucial for identifying the specific pathogen responsible for the infection, while various other workups may reveal elevated white blood cell counts, abnormal levels of inflammatory markers, or signs of organ dysfunction.
The escalating incidences of numerous risk factors, such as premature birth, low birth weight, maternal infection during pregnancy, prolonged rupture of membranes, etc., are primarily driving the neonatal sepsis market. In addition to this, the inflating utilization of effective therapeutic approaches, including antibiotics, antiviral medications, and antifungal agents, for the prompt management and treatment of the disease is also creating a positive outlook for the market. Moreover, the widespread adoption of neonatal intensive care units (NICUs) equipped with advanced medical technologies and skilled healthcare professionals is further bolstering the market growth. These specialized units are instrumental in providing critical care and monitoring to neonates suffering from sepsis, thus ensuring timely intervention and improving clinical outcomes. Apart from this, the rising awareness and emphasis on preventive measures, such as maternal screening for infections during pregnancy, early detection of risk factors, and the promotion of breastfeeding, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of supportive therapies, including mechanical ventilation and fluid management, since they help in stabilizing the patient's physiological parameters and avert life-threatening scenarios like organ failure, is also augmenting the market growth. Furthermore, the increasing demand for immunotherapy, involving the use of immunoglobulins and cytokine inhibitors, to mitigate the severity of the condition is expected to drive the neonatal sepsis market during the forecast period.
IMARC Group's new report provides an exhaustive analysis of the neonatal sepsis market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for neonatal sepsis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the neonatal sepsis market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the neonatal sepsis market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the neonatal sepsis market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current neonatal sepsis marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Key Questions Answered in this Report:
Market Insights
How has the neonatal sepsis market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the neonatal sepsis market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the neonatal sepsis market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of neonatal sepsis across the seven major markets?
What is the number of prevalent cases (2018-2034) of neonatal sepsis by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of neonatal sepsis by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with neonatal sepsis across the seven major markets?
What is the size of the neonatal sepsis patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of neonatal sepsis?
What will be the growth rate of patients across the seven major markets?
Neonatal Sepsis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for neonatal sepsis drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the neonatal sepsis market?
What are the key regulatory events related to the neonatal sepsis market?
What is the structure of clinical trial landscape by status related to the neonatal sepsis market?
What is the structure of clinical trial landscape by phase related to the neonatal sepsis market?
What is the structure of clinical trial landscape by route of administration related to the neonatal sepsis market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEONATAL SEPSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEONATAL SEPSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEONATAL SEPSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NEONATAL SEPSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEONATAL SEPSIS - UNMET NEEDS
10 NEONATAL SEPSIS - KEY ENDPOINTS OF TREATMENT
11 NEONATAL SEPSIS - MARKETED PRODUCTS
11.1 List of Neonatal Sepsis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NEONATAL SEPSIS - PIPELINE DRUGS
12.1 List of Neonatal Sepsis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 NEONATAL SEPSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 NEONATAL SEPSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEONATAL SEPSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neonatal Sepsis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neonatal Sepsis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neonatal Sepsis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neonatal Sepsis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neonatal Sepsis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neonatal Sepsis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neonatal Sepsis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neonatal Sepsis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neonatal Sepsis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neonatal Sepsis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neonatal Sepsis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neonatal Sepsis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neonatal Sepsis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neonatal Sepsis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neonatal Sepsis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neonatal Sepsis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neonatal Sepsis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neonatal Sepsis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neonatal Sepsis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neonatal Sepsis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neonatal Sepsis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neonatal Sepsis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neonatal Sepsis - Access and Reimbursement Overview
16 NEONATAL SEPSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEONATAL SEPSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEONATAL SEPSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 NEONATAL SEPSIS - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 NEONATAL SEPSIS - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 NEONATAL SEPSIS - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (2018-2034)
7.2.4 Epidemiology by Gender (2018-2034)
7.2.5 Diagnosed Cases (2018-2034)
7.2.6 Patient Pool/Treated Cases (2018-2034)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (2018-2034)
7.3.4 Epidemiology by Gender (2018-2034)
7.3.5 Diagnosed Cases (2018-2034)
7.3.6 Patient Pool/Treated Cases (2018-2034)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (2018-2034)
7.4.4 Epidemiology by Gender (2018-2034)
7.4.5 Diagnosed Cases (2018-2034)
7.4.6 Patient Pool/Treated Cases (2018-2034)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (2018-2034)
7.5.4 Epidemiology by Gender (2018-2034)
7.5.5 Diagnosed Cases (2018-2034)
7.5.6 Patient Pool/Treated Cases (2018-2034)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (2018-2034)
7.6.4 Epidemiology by Gender (2018-2034)
7.6.5 Diagnosed Cases (2018-2034)
7.6.6 Patient Pool/Treated Cases (2018-2034)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (2018-2034)
7.7.4 Epidemiology by Gender (2018-2034)
7.7.5 Diagnosed Cases (2018-2034)
7.7.6 Patient Pool/Treated Cases (2018-2034)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (2018-2034)
7.8.4 Epidemiology by Gender (2018-2034)
7.8.5 Diagnosed Cases (2018-2034)
7.8.6 Patient Pool/Treated Cases (2018-2034)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (2018-2034)
7.9.4 Epidemiology by Gender (2018-2034)
7.9.5 Diagnosed Cases (2018-2034)
7.9.6 Patient Pool/Treated Cases (2018-2034)
8 NEONATAL SEPSIS - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 NEONATAL SEPSIS - UNMET NEEDS
10 NEONATAL SEPSIS - KEY ENDPOINTS OF TREATMENT
11 NEONATAL SEPSIS - MARKETED PRODUCTS
11.1 List of Neonatal Sepsis Marketed Drugs Across the Top 7 Markets
11.1.1 Drug Name – Company Name
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the complete list of marketed drugs has been provided in the report.
12 NEONATAL SEPSIS - PIPELINE DRUGS
12.1 List of Neonatal Sepsis Pipeline Drugs Across the Top 7 Markets
12.1.1 Drug Name – Company Name
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
Kindly note that the complete list of pipeline drugs has been provided in the report.
13 NEONATAL SEPSIS - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14 NEONATAL SEPSIS – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 NEONATAL SEPSIS - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Neonatal Sepsis - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Neonatal Sepsis - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Neonatal Sepsis - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Neonatal Sepsis - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Neonatal Sepsis - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Neonatal Sepsis - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Neonatal Sepsis - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Neonatal Sepsis - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Neonatal Sepsis - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Neonatal Sepsis - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Neonatal Sepsis - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Neonatal Sepsis - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Neonatal Sepsis - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Neonatal Sepsis - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Neonatal Sepsis - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Neonatal Sepsis - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Neonatal Sepsis - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Neonatal Sepsis - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Neonatal Sepsis - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Neonatal Sepsis - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Neonatal Sepsis - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Neonatal Sepsis - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Neonatal Sepsis - Access and Reimbursement Overview
16 NEONATAL SEPSIS - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 NEONATAL SEPSIS MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 NEONATAL SEPSIS MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
